Citations

Clear

69 citation(s) found for "Feagan, Brian".

Effects of mirikizumab versus placebo on histologic inflammation evaluated by comprehensive assessment in 5 intestinal segments in a randomized controlled phase 3 trial of participants with Crohn’s disease
Feagan, Brian, D’Haens, Geert , Pai, Rish K. , Protić, Marijana , Escobar, Rodrigo , Reinisch, Walter, Jairath, Vipul , Magro, Fernando , Hertogh, Gert D. , Harpaz, Noam , Hisamatsu, T, Hon, Kam‐Lun Ellis , Owen, C, Reinisch, Walter , Siegmund, Britta

Mayo Clinic

Zeitschrift für Gastroenterologie | September 4, 2025 | Volume: 63 | Issue: No issue available | Pages: No page available

10.1055/s-0045-1810728 Get It

O21 Long-term efficacy and safety of filgotinib 200 mg in ulcerative colitis: 5-year interim data from SELECTIONLTE
Arnott, Ian , Feagan, Brian G. , Schreiber, S, Kim, Hyo Jong , Faes, Margaux , Mangili, Alexandra, Peyrin-Biroulet, Laurent, Matsuoka, Katsuyoshi , Rogler, Gerhard , Laharie, David , Vermeire, Séverine , Danese, Silvio , Loftus, Edward V. , Beales, Ian , Schreiber, Stefan , Rudolph, Christine , Peyrin‐Biroulet, Laurent

Mayo Clinic

Oral Presentations | June 23, 2025 | Volume: No volume available | Issue: No issue available | Pages: A15-A15

10.1136/gutjnl-2025-bsg.21 Get It

P68 Mirikizumab versus placebo: histologic inflammation in 5 intestinal segments in randomized controlled phase 3 trial for crohn’s disease participants
Feagan, Brian G., Hisamatsu, Tadakazu , D’Haens, Geert , Pai, Rish K. , Lin, Zhantao, Protić, Marijana , Hon, Emily, Escobar, Rodrigo , Reinisch, Walter , Dhesi, Endip , Jairath, Vipul , Magro, Fernando , Hertogh, Gert D. , Harpaz, Noam , Morris, Nathan , Owen, Charles, Reinisch, Walter

Mayo Clinic

Posters | June 23, 2025 | Volume: No volume available | Issue: No issue available | Pages: A129.2-A130

10.1136/gutjnl-2025-bsg.204 Get It

Definitions, diagnosis, and management of postoperative recurrence in Crohn’s disease patients with permanent ileostomy—a systematic review and meta-analysis
Abushamma, Suha , Yadete, Tesfaye , Nero, Neil , Falloon, Katherine , Parker, Claire E. , Ahuja, Vineet, Armuzzi, Alessandro , Bemelman, Willem A. , Bruining, David H. , Feagan, Brian G. , Hart, Ailsa, Leong, Rupert W. , Narula, Neeraj , Raine, Tim , Singh, Siddharth , Sparrow, Miles , Spinelli, Antonino , Koughnett, Julie Ann Van, Solitano, Virginia , Yuan, Yuhong , Rieder, Florian , Deepak, Parakkal , Dignass, Axel , Fulmer, Clifton , Halfvarson, Jonas , Holubar, Stefan D , Ma, C , Magro, F , McCurdy, Jeffrey D , Narula, Neeraj , Panes, Julian , Raine, Tim , Regueiro, Miguel , Spinelli, Antonino , Rieder, Florian , Solitano, Virginia , Leong, Rupert W , Abreu, María T. , Ahuja, Vineet , Deepak, Parakkal , Dotan, Iris , Fulmer, Clifton G. , Hart, Ailsa , Holubar, Stefan D. , Ma, Christopher , Magro, Fernando , Panés, Julián , Regueiro, Miguel , Rogler, Gerhard , Vuyyuru, Sudheer K. , Jairath, Vipul

Mayo Clinic

Journal of Crohn's and Colitis | March 11, 2025 | Volume: 19 | Issue: 4 | Pages: No page available

10.1093/ecco-jcc/jjaf041 | PMID 40066499 Get It

Abstract Background and Aims Over 10% of patients with Crohn’s disease require permanent ileostomy. We aimed to summarize the existing data on diagnosis, definitions of recurrence, and management of Crohn’s disease patients with permanent ileostomy. Methods MEDLINE, Embase, and CENTRAL databases were searched from inception to February 6, 2024. Randomized controlled trials, cohort and cross-sectional studies, and case series of more than 5 patients reporting on postoperative recurrence or the need for surgery in patients with Crohn’s disease and permanent ileostomy were included. Search results were independently screened, and full text of all titles meeting eligibility criteria was obtained. Outcomes of interest included diagnostic techniques, recurrence definitions, and management approaches. We estimated pooled rates (with 95% confidence interval [CI]) of recurrence. Results Thirty cohort studies including 2055 Crohn’s patients with permanent ileostomy were included (53% female, median age at the time of ileostomy creation 32 years, the most common reason for ileostomy was refractory disease). The postoperative recurrence rate was 27% (95% CI, 21.3–33.3, 26 studies, 451/1805 patients). Modalities for diagnosis of Crohn’s disease recurrence were symptoms (15 studies), endoscopy (4 studies), histology from endoscopic biopsies (2 studies), imaging (5 studies), and surgery (22 studies). The reported definitions of recurrence for each modality were heterogeneous. Conclusions There is a lack of standardized monitoring tools and criteria for diagnosing recurrence in patients with Crohn’s disease and permanent ileostomy. The results of this systematic review will form the basis of a global expert recommendation exercise focused on developing management standards and trial endpoints for this condition.
Certolizumab Pegol Treatment in Patients With Crohn’s Disease: Final Safety Data From the SECURE Registry
Lichtenstein, Gary R. , Lee, Scott D. , Feagan, Brian G. , Loftus, Edward V. , Ng, Samson , Dehlin, Kaitlin, Quinn, Paul, Coarse, Jason, Rosario-Jansen, Theresa, Arendt, C, Loftus, Edward V , Ng, Samson , Stark, Jeffrey L.

Mayo Clinic

Crohn's & Colitis 360 | January 25, 2025 | Volume: 7 | Issue: 1 | Pages: No page available

10.1093/crocol/otae083 | PMID 39895830 Get It

Abstract Background Crohn’s disease (CD) treatment is associated with increased risks of infection and malignancies. Although the safety of certolizumab pegol (CZP) is well established, long-term data from community-based observational studies are lacking. Aim This study aimed to evaluate long-term safety outcomes of patients from the SECURE registry receiving CZP relative to other CD treatments, including corticosteroids, immunosuppressants, and biologics. The primary outcome of this observational study was the evaluation of malignancies. Methods Adult patients with CD were prospectively monitored for up to 8 years. Pre-specified data were collected for all enrolled patients. Adverse events of interest (AEoIs) were reported per 100 patient-years (PY) of exposure. Incidence rate ratios (IRRs) were calculated for AEoIs using multivariate regression analysis accounting for exposure to multiple treatments. Malignancies reported after any exposure to CZP were attributed to CZP. Post-hoc analyses were conducted to evaluate non-melanoma skin cancer (NMSC), lymphoma, and pregnancy outcomes. Results A total of 3072 patients were enrolled in the study. The risk of AEoIs was similar between patients with only CZP exposure versus comparator exposure. Among patients with any CZP exposure, there was a higher frequency of serious infections (IRR: 2.56 [95% confidence interval (CI): 2.00, 3.29]) and hypersensitivity or anaphylactic reactions (IRR: 4.11 [95% CI: 1.80, 9.38]) versus patients with comparator exposure. Malignancy rates were similar across groups; however, concomitant use of thiopurines was associated with higher odds of NMSC (odds ratio: 2.30 [95% CI: 1.09, 4.89]). Most cases of lymphoma (5/7) occurred in patients with exposure to thiopurines. Pregnancy outcomes were similar across groups. Conclusions No new safety signals were identified for CZP; the use of thiopurines was identified as a risk factor for NMSC. Trial registration NCT00844285.
DOP054 Early Histologic Response and Remission are Associated With Objective Control of Inflammation After One Year of Treatment With Mirikizumab in Moderately-to-Severely Active Crohn’s Disease
Feagan, Brian G. , D’Haens, Geert , Pai, Rish K. , Protić, Marijana , Moses, Richard, Escobar, Rodrigo , Reinisch, Walter, Magro, Fernando , Jairath, Vipul , Hertogh, Gert D. , Harpaz, Noam , Hisamatsu, T, Yu, G, Luo, Weiwei , Hon, Kam‐Lun Ellis , Moses, Richard , Reinisch, Walter

Mayo Clinic

Journal of Crohn's and Colitis | January 22, 2025 | Volume: 19 | Issue: Supplement_1 | Pages: i190-i191

10.1093/ecco-jcc/jjae190.0093 Get It

Abstract Background Histologic inflammation persists in up to 1/4 of patients with Crohn’s disease (CD) despite endoscopic mucosal healing. Histologic and combined endoscopic-histologic endpoints are evolving measures of treatment efficacy in CD; however, the impact of histologic healing on long-term outcomes and disease progression is unknown. Week (W) 52 data comparing mirikizumab (Miri) vs placebo (PBO) in the randomized, double-blind, placebo- and active-controlled, treat-through Phase 3 VIVID-1 trial in patients with moderately-to-severely active CD (NCT03926130) were reported previously.1 Methods The main objective was to evaluate the association of W12 histologic response and W12 histologic remission with W52 clinical and endoscopic outcomes in VIVID-1. Two biopsy specimens from each of 5 intestinal segments (1 ileal and 4 colonic) were obtained from the edge of the ulcers, or the most inflamed mucosa from randomized patients at screening, W12, and W52. All analyses were post hoc and among patients with active histologic disease (defined as a Robarts Histopathology Index >0 and a Global Histologic Disease Activity Score >0) at baseline. Results At W12, treatment with Miri resulted in statistically significantly higher rates of achieving histologic response and histologic remission vs. PBO (Figure). At W12, 62.1% of patients had agreement (k=0.27 [fair]) between histologic response and endoscopic response, with a greater percentage achieving histologic over endoscopic response (59.0% vs. 38.8%)*. Significantly greater proportions of patients who achieved histologic response at W12 also achieved histologic response, histologic remission, endoscopic response, endoscopic remission, combined CDAI (Crohn’s Disease Activity Index) remission and endoscopic response, and normalisation of faecal calprotectin levels ≤250 µg/g and ≤150 µg/g at W52 (Table). Similar associations were observed between W12 histologic remission and W52 outcomes. Conclusion Histologic response seems to be an early objective sign of anti-inflammatory response and was significantly associated with one-year endoscopic and histologic outcomes, as well as biomarker normalisation. *Observed data References 1.Jairath V, et al. Presented at: UEGW 2024. OP131.
S1329 Effects of Mirikizumab versus Placebo on Histologic Inflammation Evaluated by Comprehensive Assessment in 5 Intestinal Segments in a Randomized, Controlled Phase 3 Trial of Participants With Crohn’s Disease
Jairath, Vipul , Feagan, Brian G. , Hisamatsu, Tadakazu , D’Haens, Geert , Pai, Rish K. , Lin, Zhantao, Protić, Marijana , Hon, Emily, Owen, Charles , Escobar, Rodrigo , Reinisch, Walter , Jairath, Vipul , Jairath, Vipul , Jairath, V , Jairath, V , Jairath, Vipul , Magro, Fernando , Hertogh, Gert D. , Harpaz, Noam , Morris, Nathan , Reinisch, Walter

Mayo Clinic

American Journal of Gastroenterology | October 24, 2024 | Volume: 119 | Issue: 10S | Pages: S952-S953

10.14309/01.ajg.0001034684.12665.85 Get It

S1146 Inflammatory Bowel Disease (IBD)-Associated Peripheral Arthritis is Not Associated With Objective Markers of Luminal IBD Disease Activity - Results From the CHASE Cohort
Abushamma, Suha , Barnes, Edward, Bhattacharya, Abhik , Cross, Raymond, Cheemalavagu, Shashank , Colombel, Jean–Frédéric, Horst, Sara N., Hou, Jason K. , Husni, M. Elaine., Scherl, Ellen , Qazi, Taha , Yang, Qijun, Cohen, Benjamin L., Feagan, Brian G., Rieder, Florian , Falloon, Katherine , Ananthakrishnan, Ashwin N. , Gore, Emily , Herfarth, Hans , Horst, Sara , Husni, M. Afif Rijal, Klein, Jeremy A. , Loftus, Edward V. , Lukin, Dana J. , Rubin, David T.

Mayo Clinic

American Journal of Gastroenterology | October 24, 2024 | Volume: 119 | Issue: 10S | Pages: S814-S815

10.14309/01.ajg.0001033952.27750.6a Get It

S1330 Effects of Mirikizumab and Ustekinumab on Histologic Inflammation Evaluated by Comprehensive Assessment in 5 Intestinal Segments in a Randomized Controlled Phase 3 Trial of Participants With Crohn’s Disease
Jairath, Vipul , Feagan, Brian G. , Hisamatsu, Tadakazu , D’Haens, Geert , Pai, Rish K. , Lin, Zhantao, Protić, Marijana , Hon, Emily, Owen, Charles , Escobar, Rodrigo , Reinisch, Walter , Jairath, Vipul , Jairath, Vipul , Jairath, V , Jairath, V , Jairath, Vipul , Magro, Fernando , Hertogh, Gert D. , Harpaz, Noam , Morris, Nathan , Reinisch, Walter

Mayo Clinic

American Journal of Gastroenterology | October 24, 2024 | Volume: 119 | Issue: 10S | Pages: S953-S953

10.14309/01.ajg.0001034688.99618.b9 Get It

Long‐term safety and efficacy of filgotinib for the treatment of moderately to severely active ulcerative colitis: Interim analysis from up to 4 years of follow‐up in the SELECTION open‐label long‐term extension study
Feagan, Brian G., Matsuoka, Katsuyoshi , Rogler, Gerhard , Laharie, David , Vermeire, Séverine , Loftus, Edward V. , Beales, Ian , Schreiber, Stefan , Kim, Hyo Jong , Faes, Margaux , Haas, Angela de, Masior, Tomasz , Rudolph, Christine , Danese, Silvio , Loftus, Edward V , Beales, Ian , Schreiber, Stefan , Peyrin-Biroulet, Laurent , Vermeire, Séverine , Danese, Silvio , Peyrin‐Biroulet, Laurent , Matsuoka, K

Mayo Clinic

Alimentary Pharmacology & Therapeutics | August 1, 2024 | Volume: 60 | Issue: 5 | Pages: 563-584

10.1111/apt.18158 | PMID 39086130 Get It

SummaryBackgroundFilgotinib, an oral, once‐daily, Janus kinase 1 preferential inhibitor, is an approved treatment for moderately to severely active ulcerative colitis.AimsThe aim of this study is to assess the safety and efficacy of continued filgotinib therapy over ~4 years in the long‐term extension of the phase 2b/3 SELECTION trial (SELECTIONLTE; NCT02914535).MethodsIn this interim analysis of SELECTIONLTE, SELECTION completers (week 10 responders to filgotinib who completed the maintenance study) continued their assigned treatment (double‐blind filgotinib 200 mg [FIL200] or filgotinib 100 mg) and SELECTION week 10 non‐responders received open‐label FIL200. We assessed safety by adverse events (AEs), and efficacy by partial Mayo Clinic Score (pMCS), inflammatory biomarkers and health‐related quality of life (HRQoL). We compared safety and efficacy between achievers and non‐achievers of a multi‐component endpoint, comprehensive disease control (CDC), comprising symptomatic, endoscopic, inflammatory biomarker and HRQoL improvements.ResultsData for completers (n = 250) and non‐responders (n = 372) were reported for ≤202 weeks. AE occurrences were low and consistent with previous analyses. The as‐observed proportion of FIL200‐treated patients in pMCS, biomarker and HRQoL remission during SELECTIONLTE remained high among completers (week 144: 80.0%, 86.4% and 86.0%, respectively) and increased among non‐responders (week 192: 62.1%, 76.7% and 59.3%, respectively). Significantly higher proportions of CDC achievers at SELECTION week 58 achieved pMCS, IBDQ and corticosteroid‐free pMCS remission than non‐achievers, up to LTE week 96.ConclusionsFilgotinib induced and maintained symptomatic remission and improved HRQoL over 4 years. Safety results showed a proven long‐term benefit–risk profile. FIL200‐treated CDC achievers had better long‐term outcomes than non‐achievers.